Table 3.
The results of sensitivity analysis
| Meta-analysis of CRP and CHD combined with depression | ||||||||
| Omitting article | Schins 200537 | Aydin Sunbul 201724 | Bankier 200925 | Lespérance 200432 | Roohafza 201836 | Ye 202244 | ||
| SMD (95% CI) | 0.57(0.25 to 0.90) | 0.52(0.15 to 0.89) | 0.49(0.14 to 0.85) | 0.58(0.26 to 0.90) | 0.45(0.08 to 0.82) | 0.38(0.14 to 0.62) | ||
| Subgroup analysis of CRP in ACS patients | ||||||||
| Omitting article | Lespérance 200432 | Roohafza 201836 | ||||||
| SMD (95%CI) | 0.73(0.41 to 1.04) | 0.14(−0.21 to 0.48) | ||||||
| Meta-analysis of hs-CRP and CHD combined with depression | ||||||||
| Omitting article | Alizadeh 202123 | Lafitte 201531 | Sforzini 201938 | Yang 201243 | ||||
| SMD (95% CI) | 0.34(0.11 to 0.58) | 0.35(0.13 to 0.58) | 0.27(0.04 to 0.50) | 0.11(−0.14 to 0.37) | ||||
| Meta-analysis of IL-6 and CHD combined with depression | ||||||||
| Omitting article | Schins 200537 | Lespérance 200432 | Roohafza36 2018 | Ye 202244 | ||||
| SMD (95% CI) | 0.60(0.10 to 1.11) | 0.62(0.16 to 1.09) | 0.32(−0.13 to 0.76) | 0.40(−0.21 to 1.02) | ||||
| Subgroup analysis of IL-6 in ACS patients | ||||||||
| Omitting article | Lespérance 200432 | Roohafza 201836 | ||||||
| SMD (95% CI) | 1.00(0.67 to 1.33) | 0.08(−0.27 to 0.42) | ||||||
| Meta-analysis of fibrinogen and CHD combined with depression | ||||||||
| Omitting article | Aydin Sunbul 201724 | Duivis 201127 | Lafitte 201531 | Whooley 200740 | ||||
| MD (95% CI) | 0.12(−0.29 to 0.52) | 0.08(−0.34 to 0.51) | 0.01(−0.33 to 0.34) | 0.23(0.06 to 0.39) | ||||
| Meta-analysis of NT-proBNP and CHD combined with depression | ||||||||
| Omitting article | Aydin Sunbul 201724 | Bankier 200925 | Ren 201735 | |||||
| SMD (95% CI) | 2.72(−2.94 to 8.39) | 2.86(−2.53 to 8.25) | 0.02(−0.26 to 0.31) | |||||
| Meta-analysis of SDNN and CHD combined with depression | ||||||||
| Omitting article | Aydin Sunbul 201724 | Frasure-Smith 200928 | Gehi 200529 | Guinjoan 200430 | Luo 201833 | Martens 200834 | Stein 200039 | Wilkowska 201942 |
| SMD (95% CI) | −0.61 (−1.12 to −0.09) |
−0.74 (−1.36 to −0.11) |
−0.75 (−1.35 to 0−.15) |
−0.68 (−1.20 to −0.16) |
−1.83 (−2.17 to −1.48) |
−0.65 (−1.18 to −0.12) |
−0.60 (−1.10 to −0.09) |
−0.65 (−1.15 to −0.15) |
| Meta-analysis of SDANN and CHD combined with depression | ||||||||
| Omitting article | Aydin Sunbul 201724 | Carney 199526 | Gehi 200529 | Martens 200834 | Stein 200039 | Whooley 200841 | ||
| MD (95% CI) | −9.53 (−17.08 to −1.99) |
−11.74 (−20.74 to −2.74) |
−16.17 (−25.94 to −6.39) |
−11.73 (−20.82 to −2.64) |
−12.22 (−21.74 to −2.71) |
−15.57 (−27.30 to −3.85) |
||
| Meta-analysis of SDNNIDX and CHD combined with depression | ||||||||
| Omitting article | Aydin Sunbul 201724 | Carney 199526 | Luo 201833 | Stein 200039 | ||||
| MD (95% CI) | −14.00(−16.26 to –11.73) | −13.87(−16.00 to –11.73) | −12.77(−16.91 to –8.63) | −13.93(−16.17 to –11.69) | ||||
| Meta-analysis of RMSSD and CHD combined with depression | ||||||||
| Omitting article | Aydin Sunbul 201724 | Carney 199526 | Luo 201833 | Martens 200834 | Stein 200039 | |||
| MD (95% CI) | −7.28(−14.44 to –0.12) | −7.65(−13.78 to –1.53) | −6.09(−11.09 to –1.08) | −10.11(−14.62 to –5.60) | −8.87(−15.66 to –2.07) | |||
| Meta-analysis of pNN50 and CHD combined with depression | ||||||||
| Omitting article | Aydin Sunbul 201724 | Carney 199526 | Guinjoan 200430 | Luo 201833 | Stein 200039 | |||
| SMD (95% CI) | −0.88(−1.60 to –0.16) | −0.92(−1.56 to –0.29) | −0.91(−1.56 to –0.26) | −0.65(−0.90 to –0.40) | −0.96(−1.57 to –0.34) | |||
ACS, acute coronary syndrome; CHD, coronary heart disease; hsCRP, high-sensitivity C reactive protein; MD, mean difference; NT-proBNP, N-terminal prohormone of brain natriuretic peptide ; RMSSD, root mean square of successive differences; SDANN, SD of the 5 min averages of all normal RR intervals; SDNN, the mean RR interval and the SD of all RR intervals; SDNNIDX, overage of the SD of all normal RR intervals for each 5 min segment; SMD, standard MD.